Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCDCC#272: Intralesional IL-2, Radiotherapy, and Pembrolizumab in Refractory Cancers
NCT03474497Phase 2Active, not recruiting
- Start
- May 2019
- Primary completion
- Apr 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC). Started May 2019; status: active, not recruiting.
02
Drugs
aldesleukin
03
Conditions
non-small cell lung cancer (NSCLC)melanomarenal cell carcinoma (RCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03474497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474497.